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T
o  ensure  the  credibility  of  research  findings 
and  to  maintain  public  trust  in  the  research 
process, it is critical that research be conducted 
transparently.  Consideration  of  how  financial,  institu-
tional and personal interests influence how research is 
designed,  conducted  and  published  is  an  increasingly 
important part of this transparency. Conflict of interest 
exists when a researcher’s private interests (competing 
interests) diverge from his or her responsibilities to the 
conduct of a research study and the publication of the re-
sults.1 Unfortunately, these competing interests are often 
not recognized2 or declared3–4; the suspicion that there 
may be undeclared competing interests has the potential 
to undermine public confidence in medical science. 
Open Medicine is delighted to publish a conflict of in-
terest checklist by Rochon and colleagues5 that provides 
a structured approach to considering and documenting 
potential  competing  interests  through  the  entire  re-
search process, from study inception to publication. De-
signed to be completed by each investigator, irrespective 
of his or her role in the study, the checklist also provides, 
for  the  first  time,  a  single  comprehensive  document 
that stakeholders with a role in a project’s adjudication 
or evaluation—members of research ethics boards and 
funding bodies, journal editors and readers—can use to 
review  and  interpret  researchers’  competing  interests 
and respond if necessary. A critical benefit of the check-
list is that it also provides a record that can be held in 
the public domain for scrutiny and evaluation over the 
course of a research project and for future reference.
We believe that the checklist has two key strengths: 
the process undertaken to develop it  6 and its broad scope. 
The checklist was developed in three phases. First, the 
research team drafted initial checklist items on the basis 
of published literature on competing interests, and two 
drafts of the checklist were reviewed by 29 and 24 re-
viewers, respectively, drawn from 3 groups (18 experts, 
12 team members and 4 research staff). In the second 
phase, a third draft was discussed by 28 participants 
in a day-long, face-to-face meeting. In the third, “con-
solidation,”  phase,  further  drafts  were  pilot-tested  for 
usability. An example document was completed using a 
hypothetical research project, and an explanatory docu-
ment and interactive PDF version were developed and 
reviewed at a second face-to-face meeting. The research 
team’s receptivity to broad user input demonstrates a 
commendable commitment to genuine knowledge trans-
lation; they have captured a wealth of knowledge and are 
disseminating it in the form of a practical product.5
The scope of the checklist is also critical. The check-
list contains four sections: administrative information, 
study information, personal financial information and 
authorship  and  contributorship  information,  covering 
processes from study inception to completion. Given the 
time frame that it covers and the breadth of information 
that it prompts users to collect, the checklist has value 
beyond  that  provided  by  the  recently  released  Inter-
national Committee of Medical Journal Editors (ICM-
JE) Uniform Disclosure Form for Potential Conflicts of 
Interest,7 which is designed to be completed by authors 
and submitted to journal editors at the time they submit 
their work for publication. The ICMJE form represents a 
final summary of an author’s relevant financial compet-
ing interests for the 36 months preceding submission of 
his or her work for publication. The ICMJE form is also 
more prescriptive than the checklist in identifying what 
constitutes a financial competing interest. Additionally, 
because the ICMJE statement is completed retrospect-
ively, it does not offer a mechanism to identify competing 
interests as they arise and hence to manage them while 
the project is underway. 
As  requirements  and  strategies  to  report  competing 
interests become increasingly important to the transpar-
ency of scientific research, there is a risk that researchers, 
as well as those who evaluate competing interests, will 
be satisfied with the simple fact that the conflicts have 
been reported, rather than seizing the opportunity as a 
community to better anticipate and manage conflicts of 
interest. The fact that Rochon and colleagues’ checklist 
is designed to be filled out throughout the lifetime of a 
study ensures that researchers will consider from the out-
set whether and how potential competing interests might influence such issues as study design and the choice of 
collaborators. This provides an opportunity for all stake-
holders to identify potential biases and manage compet-
ing interests proactively, rather than discovering at the 
publication stage that there are irreconcilable conflicts. 
In this sense it also serves as an educational tool on the 
conduct of research and brings the attention of investiga-
tors to the kinds of information that should be disclosed 
so that stakeholders can interpret a competing interest.  
The availability of a single comprehensive checklist that 
can be used by the different groups involved in evaluat-
ing a research project provides an opportunity for the re-
search team to save funding and administrative resources 
by eliminating the need to repeatedly complete different 
forms collecting similar information. Completion of the 
checklist  may  also  flag  irreconcilable  conflicts,  thereby 
allowing stakeholders to avoid investing in unpublishable 
studies. Importantly, it also helps to ensure that patients 
participate only in clinical research that has the potential 
to produce outcomes that can be published and thereafter 
applied in practice. 
We encourage readers to review both the ICMJE form 
and Rochon and colleagues’ checklist and provide feed-
back  to  their  creators  to  maximize  the  utility  of  these 
resources to these research community and the broader 
public. To this end, Open Medicine’s editors encourage 
users of the checklist to complete its associated usability 
survey, available at www.openmedicine.ca/fcoichecklist/; 
the authors are seeking feedback on the clarity and ease 
of use of the checklist as well as on its comprehensiveness 
and relevance. Although the checklist was designed for 
clinical trials, it could clearly be used more broadly, such 
as for guideline panels and research projects employing 
other study designs. We also invite you to consider this in 
your responses. Rochon and colleagues are strongly com-
mitted to developing the best possible tool for identifying 
and managing competing interests; we urge you to be part 
of this exciting evolution. 
As  further  iterations  of  this  tool  are  developed,  the 
editors  encourage  the  authors  to  consider  two  ways  to 
strengthen the checklist: by the inclusion of non-financial 
competing interests, and by giving attention to the issue 
of contributorship as well as authorship. Both of these fea-
tures are included in the ICMJE disclosure form. Includ-
ing contributors in the checklist would ensure that those 
who make substantial contributions to a manuscript but 
do not qualify for authorship according to the ICMJE cri-
teria (e.g., professional medical writers) are subject to the 
same disclosure practices. Given the ongoing lack of agree-
ment about what does or should constitute authorship,8 
lack of awareness of the ICMJE authorship criteria among 
researchers, and problems of guest and ghost authorship,9 
it may be useful to require that all contributors to a study 
declare their competing interests, rather than arbitrar-
ily limiting this requirement to the subset of contributors 
who meet the narrower definition of “author.” 
A final issue to be considered by authors, editors and 
readers is the location where completed and in-progress 
checklists should reside. We believe the checklists should 
be available in the public domain. If research is genuine-
ly free from untenable competing interests, then there 
is no need to hide this information. We recognize that 
no research is likely to be entirely conflict free; publica-
tion of the checklist provides an opportunity to broaden 
discourse rather than point the finger. Under the current 
system, journal editors and members of funding bodies 
and research ethics boards have the onus of responsibil-
ity for determining whether untenable competing inter-
ests exist. The availability of publicly archived checklists 
would allow readers and other stakeholders to determine 
for themselves how much credence should be given to 
the results of a particular research project. It would also 
ensure that media representatives are able to access in-
formation about competing interests; ideally, they would 
incorporate  this  information  into  their  reports  about 
biomedical studies.
How could checklists be published in the public do-
main?  One  option  would  be  publication  on  a  publicly 
accessible section of the website of the funding body or 
the author’s institution. Alternatively, for clinical trials 
requiring registration, the checklist could be housed at 
the same registration point as the other information on 
the trial. Authorized people could update the checklist 
as the study progressed. Journal editors publishing any 
papers arising from a research project could also publish 
the version of the checklist updated at the time of publi-
cation, along with a link to the primary archive.
It is vital that we in the research community manage 
competing interests to ensure the integrity of research; 
building public reporting of competing interests into the 
research process is critical to the principles of transpar-
ency  and  accountability.  Integrity  is  in  the  eye  of  the 
beholder, imperfect though that eye might be (even if be-
longs to a journal editor); limiting access to information 
about competing interests unnecessarily stymies others’ 
efforts  to  evaluate  them  and  makes  it  even  harder  to 
evaluate the integrity of a research project. With careful 
attention to competing interests along the full length of 
the research path, their declaration at publication need 
not open a Pandora’s box of concerns. 
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